Unresectable or Metastatic Solid Tumors

Oncology

4 drugs in development·4 companies·0 clinical trials

Drug Pipeline by Phase

Phase 1(3)

Drug	Company
EO-3021	Elevation Oncology, Inc. (ELEV)
hro761	NOVARTIS AG (NVSEF)
hro761	Novartis AG (NVS)

BLA Filed(1)

Drug	Company
larotrectinib	LOXO ONCOLOGY, INC. (LOXO)

Compare drugs

EO-3021 vs hro761 EO-3021 vs larotrectinib

Deep-dive into Unresectable or Metastatic Solid Tumors

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Unresectable or Metastatic Solid Tumors — Drugs in Development & Clinical Trials | BioSniper